NEWARK, DE--(Marketwire - June 15, 2009) - Isogen LLC announced today that it has appointed five new directors to lead key areas in finance, quality, manufacturing and business development. “These appointments are important as they signify Isogen’s next stage of evolution. We have a pipeline rich with opportunities, and now we’ve enhanced our team to put the processes in place to maximize these opportunities and deliver superior value to our customers,” shared Les Edwards, Isogen’s CEO.
With its new appointments, Isogen has added over 125 years of industry, management and leadership experience. “We’re very excited about the management team we have in place at Isogen. All of our directors -- those added recently, as well as those who have been with us from the start -- are sought-after leaders who are at the top of their game. We truly have a winning team,” commented Austin McDonald, Isogen’s COO.
Recent 2009 appointments to date include:
Mark Koscinski, CPA, has been appointed CFO and Treasurer of Isogen, and is responsible for the overall financial strength and stability of the Company. Mr. Koscinski serves as the principal financial and accounting officer of the Company, with oversight of the treasury and controllership functions. Mr. Koscinski has over 25 years’ experience in finance, with over 15 years’ experience in executive leadership. Prior to joining Isogen, Mr. Koscinski was Senior VP and CFO of Butler International, a $350 million technical services business. Mr. Koscinski was also manager at KPMG and has significant SEC experience.
Rosemarie Fisher, CPA, has been appointed Controller of Isogen. As Controller, Ms. Fisher strives to improve Isogen’s profitability by accessing a wide range of areas from budgets and performance measurements to accounting and reporting systems. Currently, Ms. Fisher is President of Real Possibilities, a management and technology firm, and serves Isogen through this company. Prior to founding Real Possibilities, Ms. Fisher held the positions of Executive VP/CFO at Pyramid Consulting, General Accounting Manager at The Hibbert Group and Corporate Accounting Officer at Tingley Rubber Corporation.
Diane Wood has been appointed Director, Quality Assurance and Regulatory Affairs. In her role, Ms. Wood is responsible for the planned and systematic compliance activities necessary to ensure each and every product and service Isogen provides to its customers meets the given requirements. A senior quality executive, Ms. Wood has over 25 years’ experience in developing quality and documentation systems and authoring multiple CMC filings and biologic applications. Prior to joining Isogen, Ms. Wood was a quality leader at Beecham Laboratories, Hoechst-Roussel Pharmaceuticals, Ortho Pharmaceuticals / Advanced Care Products, Novo Nordisk Pharmaceuticals and Serono Laboratories.
Malcolm Montgomery, Ph.D., has been appointed Director, Lab Services. In his role, Dr. Montgomery will lead Isogen’s Lab Services team in analytical method development/validation and the testing/release of pharmaceutical products. Dr. Montgomery is an analytical chemist with over 15 years’ experience in small molecule and biological drug products. Prior to joining Isogen, Dr. Montgomery held director and senior level positions at Microbac Laboratories, Centocor Research and Development, Merck, Apollon and Wyeth-Ayerst.
Robin Uhl has been appointed Director of Business Development. Working closely with the CEO, Ms. Uhl is responsible for generating revenue, building a strong sales pipeline, creating awareness of Isogen in the marketplace and developing partnerships that will propel Isogen’s growth. Ms. Uhl has over 20 years’ experience in leading marketing, communications and sales for professional services firms. Prior to joining Isogen, Ms. Uhl served as VP of Marketing for Butler International, a $350 million engineering and technology services company. In addition, Ms. Uhl has held key positions at Arthur Andersen and Dun and Bradstreet.
These leaders round out the senior management team and join the following valued directors at Isogen:
Robert Serra, VP, Product Technology Robert Roy, Director, Manufacturing Peter Terras, Director, Engineering Denise Verruno, Director, Corporate Administration
About Isogen
Through its Science Center in Newark, Delaware, Isogen provides advanced sterile manufacturing for potent and non-potent therapeutics for the critical clinical/commercial scale manufacturing transition. The Company delivers a fully integrated suite of services including formulation, tech transfer, laboratory, and validation services for the contract filling of liquids and lyophilized formulations for vaccines, mAbs, and other synthetic and biologically derived therapeutics. For further information, contact Robin Uhl, ruhl@isogenllc.com, 201-394-1927.
Information contained in this press release, other than historical information, may be considered forward-looking in nature as such it is based upon certain assumptions and is subject to various risks and uncertainties, which may not be controllable by the Company. To the extent that these assumptions prove to be incorrect, or should any of these risks or uncertainties materialize, the actual results may vary materially from those that were anticipated.
CONTACT:
Robin Uhl
Isogen
201.394.1927
Email Contact
